Analysis for effect of Eicosapentaenoic acid (EPA) on aberrant crypt foci (ACF)
Phase 3
- Conditions
- Subjects with aberrant crypt foci (ACF)
- Registration Number
- JPRN-UMIN000001551
- Lead Sponsor
- Gastroenterology Division, Yokohama City University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
a. Liver cirrhosis or chronic hepatic, chronic renal failure b. Women who are pregnant or with a possibility of pregnancy c. Alcohol dependence or drug dependence d. Drug allergy e. Heart failure f. Hemorrhagic g. Those who have started to use other medication or dietary supplement in study period h. The patient that it is already taken EPA i. History of colorectal cancer j. Family history of colorectal cancer k. The patient currently taking NSAIDs l. Inadequate to entry to this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Observation of ACF and polyps using magnifying endoscopy
- Secondary Outcome Measures
Name Time Method